The costs, derived from patient charges, were reported as aggregated totals for each patient. The costs for home-based care included charges for infliximab, nursing services, supplies and laboratory samples. In addition to these items, the costs reported for hospital-based care included the cost of physician visits. Discounting was not necessary because of the short time horizon involved. The cost per 100 mg infliximab was reported without breakdowns, either by quantity or by unit cost of individual resource components. All the costs appear to have been reported from a purchaser perspective, without including the patient's transport costs. There was no mention of adjustment for inflation. All the costs would appear to relate to the data abstraction period (September 2001 to October 2003).